{"id":"folferi-and-celecoxib","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Cardiovascular events (celecoxib-related)"}]},"_chembl":{"chemblId":"CHEMBL118","moleculeType":"Small molecule","molecularWeight":"381.38"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FOLFIRI is a combination chemotherapy regimen (fluorouracil, leucovorin, and irinotecan) that damages DNA and inhibits topoisomerase I in rapidly dividing cancer cells. Celecoxib is a selective COX-2 inhibitor that reduces prostaglandin production, potentially decreasing inflammation and angiogenesis in tumors. The combination aims to enhance anti-tumor efficacy through dual mechanisms.","oneSentence":"FOLFIRI chemotherapy combined with celecoxib inhibits tumor cell division through fluorouracil and irinotecan while reducing inflammation via COX-2 inhibition.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:39:42.481Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer (based on FOLFIRI standard use with celecoxib as adjunctive agent)"}]},"trialDetails":[{"nctId":"NCT03645187","phase":"PHASE4","title":"Celecoxib as Adjuvant Therapy to Chemotherapy in Patients With Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Sherief Abd-Elsalam","startDate":"2018-08-01","conditions":"Colon Cancer Stage","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Folferi and celecoxib","genericName":"Folferi and celecoxib","companyName":"Sherief Abd-Elsalam","companyId":"sherief-abd-elsalam","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FOLFIRI chemotherapy combined with celecoxib inhibits tumor cell division through fluorouracil and irinotecan while reducing inflammation via COX-2 inhibition. Used for Colorectal cancer (based on FOLFIRI standard use with celecoxib as adjunctive agent).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}